Journal
TRIALS
Volume 23, Issue 1, Pages -Publisher
BMC
DOI: 10.1186/s13063-022-06220-0
Keywords
Acute respiratory distress syndrome; Mesenchymal stromal cells; MSCs; Mesenchymal stem cells; Clinical trial; Protocol; COVID-19
Categories
Funding
- Wellcome Trust Health Innovation Challenge Fund [106939/Z/15/Z]
- Research and Development Division of the Public Health Agency (Northern Ireland)
- Wellcome Trust [106939/Z/15/Z] Funding Source: Wellcome Trust
Ask authors/readers for more resources
This study aims to evaluate the safety and efficacy of a novel umbilical cord-derived mesenchymal stromal cell product (REALIST ORBCEL-C) in patients with ARDS due to COVID-19 and other causes. The trial consists of two phases: a dose-escalation pilot trial and a randomized, placebo-controlled trial. The primary outcomes include the incidence of serious adverse events and oxygenation index at day 7. The study will be reported according to the CONSORT 2010 statement.
Background: Mesenchymal stromal cells (MSCs) may be of benefit in ARDS due to immunomodulatory and reparative properties. This trial investigates a novel CD362 enriched umbilical cord derived MSC product (REALIST ORBCEL-C), produced to Good Manufacturing Practice standards, in patients with moderate to severe ARDS due to COVID-19 and ARDS due to other causes. Methods: Phase 1 is a multicentre open-label dose-escalation pilot trial. Patients will receive a single infusion of REALIST ORBCEL-C (100 x 10(6) cells, 200 x 10(6) cells or 400 x 10(6) cells) in a 3 + 3 design. Phase 2 is a multicentre randomised, triple blind, allocation concealed placebo-controlled trial. Two cohorts of patients, with ARDS due to COVID-19 or ARDS due to other causes, will be recruited and randomised 1:1 to receive either a single infusion of REALIST ORBCEL-C (400 x 10(6) cells or maximal tolerated dose in phase 1) or placebo. Planned recruitment to each cohort is 60 patients. The primary safety outcome is the incidence of serious adverse events. The primary efficacy outcome is oxygenation index at day 7. The trial will be reported according to the Consolidated Standards for Reporting Trials (CONSORT 2010) statement. Discussion: The development and manufacture of an advanced therapy medicinal product to Good Manufacturing Practice standards within NHS infrastructure are discussed, including challenges encountered during the early stages of trial set up. The rationale to include a separate cohort of patients with ARDS due to COVID-19 in phase 2 of the trial is outlined.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available